Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Onkologie 2011; 34: 362-367.
- Schlagwort
-
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2013
- Beteiligte Personen und Organisationen
-
Beckmann, Matthias W.
Brucker, Cosima
Hanf, Volker
Rauh, Claudia
Bani, Mayada R.
Knob, Stefanie
Petsch, Sabrina
Schick, Stefan
Fasching, Peter A.
Hartmann, Arndt
Lux, Michael P.
Häberle, Lothar
- URN
-
urn:nbn:de:bvb:29-opus-42966
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:44 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Beckmann, Matthias W.
- Brucker, Cosima
- Hanf, Volker
- Rauh, Claudia
- Bani, Mayada R.
- Knob, Stefanie
- Petsch, Sabrina
- Schick, Stefan
- Fasching, Peter A.
- Hartmann, Arndt
- Lux, Michael P.
- Häberle, Lothar
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2013
Ähnliche Objekte (12)
Invasive Breast Cancer: Recognition of Molecular Subtypes
Are Certified Breast Centers Cost-Effective?
Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma
Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis
Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
Invasive Breast Cancer: Recognition of Molecular Subtypes
Are Certified Breast Centers Cost-Effective?
Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma
Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis
Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
Invasive Breast Cancer: Recognition of Molecular Subtypes
Are Certified Breast Centers Cost-Effective?
Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma
Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis
Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer